Similar to our observations, targeting CD38+ Tregs with the CD38 monoclonal antibody isatuximab in patients with multiple myeloma has been shown to alleviate Tregs-mediated suppression and concurrently improve the effector response of natural killer (NK) and CD8+ T cells, without any systemic toxicity (22). Here, CD38 is linked to plasma cell myeloma.